LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.

Huang, Boxuan / Ling, Rongsong / Cheng, Yifan / Wen, Jieqi / Dai, Yarong / Huang, Wenjie / Zhang, Siyan / Lu, Xifeng / Luo, Yifeng / Jiang, Yi-Zhou

Molecular therapy. Methods & clinical development

2020 Volume 18, Page(s) 367–375

Abstract: The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused ... by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected ... the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular ...

Abstract	The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world. Currently there is no effective proven drug for the treatment of COVID-19; therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2 and introduce its infection and replication process. Then, we review the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19.
Keywords	covid19
Language	English
Publishing date	2020-06-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2872938-9
ISSN	2329-0501 ; 2329-0501
ISSN (online)	2329-0501
ISSN	2329-0501
DOI	10.1016/j.omtm.2020.06.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7107: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Huang, Boxuan / Ling, Rongsong / Cheng, Yifan / Wen, Jieqi / Dai, Yarong / Huang, Wenjie / Zhang, Siyan / Lu, Xifeng / Luo, Yifeng / Jiang, Yi-Zhou

Mol. Ther. Methods Clin. Dev.

Abstract: The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused ... therapeutic drugs and options has become more urgent. In this review, Boxuan Huang et al. mainly focus ... by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected ...

Abstract	The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world. Currently there is no effective proven drug for the treatment of COVID-19; therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2 and introduce its infection and replication process. Then, we review the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19. With the global pandemic of COVID-19, the development of effective therapeutic drugs and options has become more urgent. In this review, Boxuan Huang et al. mainly focus on the characteristics of COVID-19, the key molecular targets of SARS-CoV-2, relative drug clinical trial results, and progress in vaccine development.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #644785
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Boxuan Huang / Rongsong Ling / Yifan Cheng / Jieqi Wen / Yarong Dai / Wenjie Huang / Siyan Zhang / Xifeng Lu / Yifeng Luo / Yi-Zhou Jiang

Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 367-

2020 Volume 375

Abstract	The coronavirus disease 2019 (COVID-19) is a new type of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. COVID-19 is affecting millions of patients, and the infected number keeps increasing. SARS-CoV-2 is highly infectious, has a long incubation period, and causes a relatively high death rate, resulting in severe health problems all over the world. Currently there is no effective proven drug for the treatment of COVID-19; therefore, development of effective therapeutic drugs to suppress SARS-CoV-2 infection is urgently needed. In this review, we first summarize the structure and genome features of SARS-CoV-2 and introduce its infection and replication process. Then, we review the clinical symptoms, diagnosis, and treatment options of COVID-19 patients. We further discuss the potential molecular targets and drug development strategies for treatment of the emerging COVID-19. Finally, we summarize clinical trials of some potential therapeutic drugs and the results of vaccine development. This review provides some insights for the treatment of COVID-19.
Keywords	Genetics ; QH426-470 ; Cytology ; QH573-671 ; covid19
Subject code	610
Language	English
Publishing date	2020-09-01T00:00:00Z
Publisher	Elsevier
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Clinical Characteristics, Laboratory Findings, Management, and Outcome of Severe Coronavirus Disease 2019 in Children at a Tertiary Care Center in Riyadh, Saudi Arabia: A Retrospective Study.

AlMayouf, AbdulAziz / AlShahrani, Dayel / AlGhain, Salwan / AlFaraj, Sarah / Bashawri, Yara / AlFawaz, Tariq / AlDosari, Egab / Al-Awdah, Laila / AlShehri, Mohammed / AlGoraini, Yara

Frontiers in pediatrics

2022 Volume 10, Page(s) 865441

Abstract: ... resulted in death. Future studies will be crucial to better understand the disease spectrum and potential ... infection in children and the therapeutic interventions used.: Methods: This retrospective cohort study ... related (98%), and the common physical sign was fever (49%). High D-dimer (90.7%) and C-reactive protein ...

Abstract	Background: Numerous studies worldwide have reported COVID-19 in children; however, the clinical symptoms and consequences of COVID-19 in children have only been reported in a few studies in Saudi and gulf region. Therefore, we aimed to investigate the clinical features and outcomes of COVID-19 infection in children and the therapeutic interventions used. Methods: This retrospective cohort study included 96 patients with confirmed severe acute respiratory syndrome coronavirus 2 infection aged ≤14 years who were admitted to a tertiary governmental care hospital in Riyadh, Saudi Arabia between March 2020 and November 2020. Data on children with COVID-19, including demographics, comorbidities, symptoms, imaging and laboratory results, therapies, and clinical outcomes, were analyzed. Results: Of 96 children admitted with a confirmed diagnosis of COVID-19, 63.8% were aged ≤ 3 years, 52.1% were male, 56.2% had an unknown source of infection, and 51% had no comorbidities. Most cases had severe infection (71.88%) as they required oxygen, 10.42% of whom were critical. The most common symptoms were respiratory-related (98%), and the common physical sign was fever (49%). High D-dimer (90.7%) and C-reactive protein (72.09%) levels were found in most cases. Oxygen (71.88%) was the most commonly used treatment. Most patients were discharged home and fully recovered (97.92%). We reported two deaths (2.08%). Conclusions: Our findings showed that the majority of the admitted children with COVID-19 were ≤3 years of age (52.1%) and infected with an unknown source (56.2%). Moreover, the majority of the cases had severe COVID-19 infection as they required oxygen (71.88%), although they had favorable outcomes. However, some cases were critical and resulted in death. Future studies will be crucial to better understand the disease spectrum and potential therapeutic options for COVID-19 in children.
Language	English
Publishing date	2022-05-03
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2711999-3
ISSN	2296-2360
ISSN	2296-2360
DOI	10.3389/fped.2022.865441
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Characteristics of COVID and post COVID polyneuropathies in adults and pediatrics: an Egyptian sample.

Elshebawy, Haidy / Ezzeldin, Mohamed Y / Elzamarany, Eman Hassan

The Egyptian journal of neurology, psychiatry and neurosurgery

2021 Volume 57, Issue 1, Page(s) 178

Abstract: ... understanding of the underlying pathophysiology and therapeutic options of polyneuropathies related to COVID-19 ... with coronavirus disease 2019 : Case presentation: This study was conducted on 42 patients, they were divided ... into two groups, group (A) and group (B) in first and second waves respectively. Twenty-five patients ...

Abstract	Background: The aim of this study is to describe the different forms of polyneuropathy associated with coronavirus disease 2019 Case presentation: This study was conducted on 42 patients, they were divided into two groups, group (A) and group (B) in first and second waves respectively. Twenty-five patients presented by ascending weakness preceded by fever, dry cough and respiratory distress, electromyography (EMG) and nerve conduction (NC) studies done and confirmed the clinical diagnosis of demyelinating polyneuropathy. Eight patients presented by acute flaccid quadriparesis, more severe in upper limbs preceded by fever and diarrhea diagnosed as acute axonal polyneuropathy. Five patients presented by severe fatigue and progressive weakness of both lower and upper limbs, they developed fever and cough 10 days after the neurological symptoms. EMG and NC done and confirmed clinical diagnosis of polyneuropathy of demyelinating with secondary axonal picture. Four patients presented 30 to 40 days after their recovery form corona virus infection with gradual progressive weakness of both upper and lower limbs over 2 to 3 months duration, mainly the proximal muscles of lower limbs were affected with areflexia. EMG and NC done and confirmed the diagnosis of chronic inflammatory demyelinating polyneuropathy Conclusion: We should gain a better understanding of the underlying pathophysiology and therapeutic options of polyneuropathies related to COVID-19, which will have an impact on the treatment of the COVID related respiratory failure presenting with neuropathy.
Language	English
Publishing date	2021-12-20
Publishing country	England
Document type	Journal Article
ZDB-ID	2686351-0
ISSN	1687-8329 ; 1110-1083
ISSN (online)	1687-8329
ISSN	1110-1083
DOI	10.1186/s41983-021-00435-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.

Santos-Sánchez, Norma Francenia / Salas-Coronado, Raúl

Medwave

2020 Volume 20, Issue 8, Page(s) e8037

Abstract: ... hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated ... Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease ... 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected ...

Title translation	Origen, características estructurales, medidas de prevención, diagnóstico y fármacos potenciales para prevenir y controlar COVID-19.
Abstract	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes COVID-19 (Coronavirus disease 2019). This disease was detected in the city of Wuhan in China in December 2019. People infected with COVID-19 shows varying manifestations, depending on their health and age. The most common symptoms are fever, cough, myalgia, fatigue, odynophagia, and dyspnea. Infected adults older 60 years of age are the group of patients most susceptible to severe COVID-19 states and present comor-bidity in the presence of chronic diseases. On the other hand, it is also essential to have tests to detect SARS-COV-2 in people and follow the evolution of COVID-19 quickly, reliably, and cheap. To achieve this, there are real-time reverse transcription pol-ymerase chain reaction (RT-PCR) tests, isothermal nucleic acid amplification, and enzyme immunostimulation. Currently, there are no drug treatments to prevent infection and to combat the virus's effects. However, different research groups that are conduct-ing in vitro, in vivo, and in silico tests to find drugs able to provide an immune response and to control infection in humans with SARS-CoV-2. Chloroquine, hydroxychloroquine, remdesivir, interferon-2b, and oseltamivir are some pharmacological options evaluated in clinical trials for prophylaxis of COVID-19. The purpose of this review is to establish a reference framework for taxonomic classification of SARS-CoV-2 and the relationship they have with other CoVs, as well as their structure and propaga-tion pathways in humans. The characteristics and symptoms presented by patients with COVID-19, the detection methods, and possible treatments are also presented.
MeSH term(s)	Age Factors ; Betacoronavirus/classification ; Betacoronavirus/isolation & purification ; Clinical Laboratory Techniques ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Humans ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Risk Factors
Keywords	covid19
Language	English
Publishing date	2020-09-25
Publishing country	Chile
Document type	Journal Article ; Review
ZDB-ID	2818022-7
ISSN	0717-6384 ; 0717-6384
ISSN (online)	0717-6384
ISSN	0717-6384
DOI	10.5867/medwave.2020.08.8037
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation-A Retrospective Cohort Study.

Roedl, Kevin / Kahn, Ahmel / Jarczak, Dominik / Fischer, Marlene / Boenisch, Olaf / de Heer, Geraldine / Burdelski, Christoph / Frings, Daniel / Sensen, Barbara / Nierhaus, Axel / Braune, Stephan / Yildirim, Yalin / Bernhardt, Alexander / Reichenspurner, Hermann / Kluge, Stefan / Wichmann, Dominic

Journal of clinical medicine

2021 Volume 10, Issue 22

Abstract: ... in patients suffering from coronavirus disease 2019 (COVID-19). VV-ECMO was also frequently utilised during ... included. Patient characteristics, parameters related to ICU and vv/va-ECMO as well as clinical outcomes ... were included, 52 (46%) with COVID-19 and 61 (54%) with influenza-related ARDS. Median age of patients ...

Abstract	Extracorporeal membrane oxygenation (ECMO) represents a viable therapy option for patients with refractory acute respiratory distress syndrome (ARDS). Currently, veno-venous (vv) ECMO is frequently used in patients suffering from coronavirus disease 2019 (COVID-19). VV-ECMO was also frequently utilised during the influenza pandemic and experience with this complex and invasive treatment has increased worldwide since. However, data on comparison of clinical characteristics and outcome of patients with COVID-19 and influenza-related severe ARDS treated with vv-ECMO are scarce. This is a retrospective analysis of all consecutive patients treated with vv/(veno-arterial)va-ECMO between January 2009 and January 2021 at the University Medical Centre Hamburg-Eppendorf in Germany. All patients with confirmed COVID-19 or influenza were included. Patient characteristics, parameters related to ICU and vv/va-ECMO as well as clinical outcomes were compared. Mortality was assessed up to 90 days after vv/va-ECMO initiation. Overall, 113 patients were included, 52 (46%) with COVID-19 and 61 (54%) with influenza-related ARDS. Median age of patients with COVID-19 and influenza was 58 (IQR 53-64) and 52 (39-58) years (
Language	English
Publishing date	2021-11-21
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm10225440
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation—A Retrospective Cohort Study

Kevin Roedl / Ahmel Kahn / Dominik Jarczak / Marlene Fischer / Olaf Boenisch / Geraldine de Heer / Christoph Burdelski / Daniel Frings / Barbara Sensen / Axel Nierhaus / Stephan Braune / Yalin Yildirim / Alexander Bernhardt / Hermann Reichenspurner / Stefan Kluge / Dominic Wichmann

Journal of Clinical Medicine, Vol 10, Iss 5440, p

2021 Volume 5440

Abstract	Extracorporeal membrane oxygenation (ECMO) represents a viable therapy option for patients with refractory acute respiratory distress syndrome (ARDS). Currently, veno-venous (vv) ECMO is frequently used in patients suffering from coronavirus disease 2019 (COVID-19). VV-ECMO was also frequently utilised during the influenza pandemic and experience with this complex and invasive treatment has increased worldwide since. However, data on comparison of clinical characteristics and outcome of patients with COVID-19 and influenza-related severe ARDS treated with vv-ECMO are scarce. This is a retrospective analysis of all consecutive patients treated with vv/(veno-arterial)va-ECMO between January 2009 and January 2021 at the University Medical Centre Hamburg-Eppendorf in Germany. All patients with confirmed COVID-19 or influenza were included. Patient characteristics, parameters related to ICU and vv/va-ECMO as well as clinical outcomes were compared. Mortality was assessed up to 90 days after vv/va-ECMO initiation. Overall, 113 patients were included, 52 (46%) with COVID-19 and 61 (54%) with influenza-related ARDS. Median age of patients with COVID-19 and influenza was 58 (IQR 53–64) and 52 (39–58) years ( p < 0.001), 35% and 31% ( p = 0.695) were female, respectively. Charlson Comorbidity Index was 3 (1–5) and 2 (0–5) points in the two groups ( p = 0.309). Median SAPS II score pre-ECMO was 27 (24–36) vs. 32 (28–41) points ( p = 0.009), and SOFA score was 13 (11–14) vs. 12 (8–15) points ( p = 0.853), respectively. Median P/F ratio pre-ECMO was 64 (46–78) and 73 (56–104) ( p = 0.089); pH was 7.20 (7.16–7.29) and 7.26 (7.18–7.33) ( p = 0.166). Median days on vv/va-ECMO were 17 (7–27) and 11 (7–20) ( p = 0.295), respectively. Seventy-one percent and sixty-nine percent had renal replacement therapy ( p = 0.790). Ninety-four percent of patients with COVID-19 and seventy-seven percent with influenza experienced vv/va-ECMO-associated bleeding events ( p = 0.004). Thirty-four percent and fifty-five percent were successfully ...
Keywords	COVID-19 ; coronavirus disease ; influenza ; multiple organ failure ; ARDS ; ECMO ; Medicine ; R
Subject code	610 ; 616
Language	English
Publishing date	2021-11-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Search results

Search options

Article: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Kategorien

Inter-library loan at ZB MED

Article ; Online: Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Article: Clinical Characteristics, Laboratory Findings, Management, and Outcome of Severe Coronavirus Disease 2019 in Children at a Tertiary Care Center in Riyadh, Saudi Arabia: A Retrospective Study.

More links

Kategorien

Order via subito

Article: Characteristics of COVID and post COVID polyneuropathies in adults and pediatrics: an Egyptian sample.

More links

Kategorien

Order via subito

Article ; Online: Origin, structural characteristics, prevention measures, diagnosis and potential drugs to prevent and COVID-19.

More links

Kategorien

Order via subito

Article: Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation-A Retrospective Cohort Study.

More links

Kategorien

Order via subito

Article ; Online: Clinical Characteristics, Complications and Outcomes of Patients with Severe Acute Respiratory Distress Syndrome Related to COVID-19 or Influenza Requiring Extracorporeal Membrane Oxygenation—A Retrospective Cohort Study

Full text online

More links

Kategorien

Inter-library loan at ZB MED